Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in systemic sclerosis-associated interstitial lung disease
jRCT2080223110Phase 3Completed
- Start
- Feb 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity (FVC). Started Feb 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on jRCT2080223110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223110.